Back to Search Start Over

Effect of vitamin D supplementation on depression in older Australian adults.

Authors :
Rahman, Sabbir T.
Waterhouse, Mary
Romero, Briony Duarte
Baxter, Catherine
English, Dallas R.
Almeida, Osvaldo P.
Berk, Michael
Ebeling, Peter R.
Armstrong, Bruce K.
McLeod, Donald S. A.
Hartel, Gunter
O'Connell, Rachel L.
Pham, Hai
Scott, James G.
van der Pols, Jolieke C.
Venn, Alison J.
Webb, Penelope M.
Whiteman, David C.
Neale, Rachel E.
Source :
International Journal of Geriatric Psychiatry; Jan2023, Vol. 38 Issue 1, p1-13, 13p
Publication Year :
2023

Abstract

<bold>Objectives: </bold>To investigate whether vitamin D supplementation reduces depressive symptoms and incidence of antidepressant use.<bold>Methods: </bold>We used data from the D-Health Trial (N = 21,315), a randomized double-blind placebo-controlled trial of monthly vitamin D3 for the prevention of all-cause mortality. Participants were Australians aged 60-84 years. Participants completed the Patient Health Questionnaire (PHQ-9) at 1, 2 and 5 years after randomization to measure depressive symptoms; national prescribing records were used to capture antidepressant use. We used mixed models and survival models.<bold>Results: </bold>Analyses of PHQ-9 scores included 20,487 participants (mean age 69·3 years, 46% women); the mean difference (MD) in PHQ-9 score (vitamin D vs. placebo) was 0·02 (95% CI -0·06, 0·11). There was negligible difference in the prevalence of clinically relevant depression (PHQ-9 score ≥10) (odds ratio 0·99; 95% CI 0·90, 1·08). We included 16,670 participants in the analyses of incident antidepressant use (mean age 69·4 years, 43% women). Incidence of antidepressant use was similar between the groups (hazard ratio [HR] 1·04; 95% CI 0·96, 1·12). In subgroup analyses, vitamin D improved PHQ-9 scores in those taking antidepressants at baseline (MD -0·25; 95% CI -0·49, -0·01; p-interaction = 0·02). It decreased risk of antidepressant use in participants with predicted 25(OH)D concentration <50 nmol/L (HR 0·88; 95% CI 0·75, 1·02; p-interaction = 0·01) and increased risk in those with predicted 25(OH)D ≥ 50 nmol/L (HR 1·10; 95% CI 1·01, 1·20).<bold>Conclusion: </bold>Monthly supplementation with high-dose vitamin D3 was not of benefit for measures of depression overall, but there was some evidence of benefit in subgroup analyses.<bold>Clinical Trial Registration: </bold>The trial is registered on the Australian New Zealand Clinical Trials Registry: ACTRN12613000743763. https://www.anzctr.org.au/. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
08856230
Volume :
38
Issue :
1
Database :
Complementary Index
Journal :
International Journal of Geriatric Psychiatry
Publication Type :
Academic Journal
Accession number :
161096603
Full Text :
https://doi.org/10.1002/gps.5847